The therapeutic potential of interleukin-10 in neuroimmune diseases

Simple item page
dc.contributor.authorKwilasz, A.J.
dc.contributor.authorGrace, P.M.
dc.contributor.authorSerbedzija, P.
dc.contributor.authorMaier, S.F.
dc.contributor.authorWatkins, L.R.
dc.date.issued2015
dc.description.abstractNeuroimmune diseases have diverse symptoms and etiologies but all involve pathological inflammation that affects normal central nervous system signaling. Critically, many neuroimmune diseases also involve insufficient signaling/bioavailability of interleukin-10 (IL-10). IL-10 is a potent anti-inflammatory cytokine released by immune cells and glia, which drives the regulation of a variety of anti-inflammatory processes. This review will focus on the signaling pathways and function of IL-10, the current evidence for insufficiencies in IL-10 signaling/bioavailability in neuroimmune diseases, as well as the implications for IL10-based therapies to treating such problems. We will review in detail four pathologies as examples of the common etiologies of such disease states, namely neuropathic pain (nerve trauma), osteoarthritis (peripheral inflammation), Parkinson's disease (neurodegeneration), and multiple sclerosis (autoimmune). A number of methods to increase IL-10 have been developed (e.g. protein administration, viral vectors, naked plasmid DNA, plasmid DNA packaged in polymers to enhance their uptake into target cells, and adenosine 2A agonists), which will also be discussed. In general, IL-10-based therapies have been effective at treating both the symptoms and pathology associated with various neuroimmune diseases, with more sophisticated gene therapy-based methods producing sustained therapeutic effects lasting for several months following a single injection. These exciting results have resulted in IL-10-targeted therapeutics being positioned for upcoming clinical trials for treating neuroimmune diseases, including neuropathic pain. Although further research is necessary to determine the full range of effects associated with IL-10-based therapy, evidence suggests IL-10 may be an invaluable target for the treatment of neuroimmune disease.
dc.description.statementofresponsibilityA.J. Kwilasz, P.M. Grace, P. Serbedzija, S.F. Maier, L.R. Watkins
dc.identifier.citationNeuropharmacology, 2015; 96(PA):55-69
dc.identifier.doi10.1016/j.neuropharm.2014.10.020
dc.identifier.issn0028-3908
dc.identifier.issn1873-7064
dc.identifier.orcidGrace, P.M. [0000-0002-8999-1220]
dc.identifier.urihttps://hdl.handle.net/2440/133861
dc.language.isoen
dc.publisherElsevier
dc.rights© 2014 Elsevier Ltd. All rights reserved.
dc.source.urihttps://doi.org/10.1016/j.neuropharm.2014.10.020
dc.subjectInterleukin-10; Interleukin-10 receptor; Neuropathic pain; Osteoarthritis; Parkinson's disease; Multiple sclerosis
dc.subject.meshAnimals
dc.subject.meshHumans
dc.subject.meshOsteoarthritis
dc.subject.meshMultiple Sclerosis
dc.subject.meshParkinson Disease
dc.subject.meshNeuralgia
dc.subject.meshInflammation
dc.subject.meshInterleukin-10
dc.subject.meshDrug Delivery Systems
dc.subject.meshSignal Transduction
dc.subject.meshNeuroimmunomodulation
dc.subject.meshFemale
dc.subject.meshMale
dc.titleThe therapeutic potential of interleukin-10 in neuroimmune diseases
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications